Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Advanced Esophageal Squamous Cell Carcinoma
NCT02649361Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- anlotinib
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 2, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Anlotinib with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Started Jan 2016; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Anlotinib
Anlotinib QD PO
Placebo
Placebo QD PO
03
Who it enrols
Patients with advanced esophageal squamous cell carcinoma who have failed platinum-based or paclitaxel-containing chemotherapy, with measurable disease and adequate organ function.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Objective Response Rate
Disease Control Rate
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT02649361.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649361.